Literature DB >> 19125387

Simulating competing risks data in survival analysis.

Jan Beyersmann1, Aurélien Latouche, Anika Buchholz, Martin Schumacher.   

Abstract

Competing risks analysis considers time-to-first-event ('survival time') and the event type ('cause'), possibly subject to right-censoring. The cause-, i.e. event-specific hazards, completely determine the competing risk process, but simulation studies often fall back on the much criticized latent failure time model. Cause-specific hazard-driven simulation appears to be the exception; if done, usually only constant hazards are considered, which will be unrealistic in many medical situations. We explain simulating competing risks data based on possibly time-dependent cause-specific hazards. The simulation design is as easy as any other, relies on identifiable quantities only and adds to our understanding of the competing risks process. In addition, it immediately generalizes to more complex multistate models. We apply the proposed simulation design to computing the least false parameter of a misspecified proportional subdistribution hazard model, which is a research question of independent interest in competing risks. The simulation specifications have been motivated by data on infectious complications in stem-cell transplanted patients, where results from cause-specific hazards analyses were difficult to interpret in terms of cumulative event probabilities. The simulation illustrates that results from a misspecified proportional subdistribution hazard analysis can be interpreted as a time-averaged effect on the cumulative event probability scale.

Entities:  

Mesh:

Year:  2009        PMID: 19125387     DOI: 10.1002/sim.3516

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  37 in total

1.  Hierarchical likelihood inference on clustered competing risks data.

Authors:  Nicholas J Christian; Il Do Ha; Jong-Hyeon Jeong
Journal:  Stat Med       Date:  2015-08-16       Impact factor: 2.373

Review 2.  Applying competing risks regression models: an overview.

Authors:  Bernhard Haller; Georg Schmidt; Kurt Ulm
Journal:  Lifetime Data Anal       Date:  2012-09-26       Impact factor: 1.588

3.  A multi-state model based reanalysis of the Framingham Heart Study: Is dementia incidence really declining?

Authors:  Nadine Binder; James Balmford; Martin Schumacher
Journal:  Eur J Epidemiol       Date:  2019-10-14       Impact factor: 8.082

4.  Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?

Authors:  James F Troendle; Eric S Leifer; Lauren Kunz
Journal:  Stat Med       Date:  2018-04-29       Impact factor: 2.373

5.  Cause-Specific Hazard Regression for Competing Risks Data Under Interval Censoring and Left Truncation.

Authors:  Chenxi Li
Journal:  Comput Stat Data Anal       Date:  2016-07-14       Impact factor: 1.681

6.  Nonparametric Assessment of Differences Between Competing Risk Hazard Ratios: Application to Racial Differences in Pediatric Chronic Kidney Disease Progression.

Authors:  Derek K Ng; Daniel A Antiporta; Matthew B Matheson; Alvaro Muñoz
Journal:  Clin Epidemiol       Date:  2020-01-20       Impact factor: 4.790

7.  Nomogram for survival analysis in the presence of competing risks.

Authors:  Zhongheng Zhang; Ronald B Geskus; Michael W Kattan; Haoyang Zhang; Tongyu Liu
Journal:  Ann Transl Med       Date:  2017-10

8.  Joint Inference for Competing Risks Survival Data.

Authors:  Gang Li; Qing Yang
Journal:  J Am Stat Assoc       Date:  2016-10-18       Impact factor: 5.033

9.  A pseudo-likelihood method for estimating misclassification probabilities in competing-risks settings when true-event data are partially observed.

Authors:  Philani B Mpofu; Giorgos Bakoyannis; Constantin T Yiannoutsos; Ann W Mwangi; Margaret Mburu
Journal:  Biom J       Date:  2020-06-10       Impact factor: 2.207

10.  Analyzing Competing Risk Data Using the R timereg Package.

Authors:  Thomas H Scheike; Mei-Jie Zhang
Journal:  J Stat Softw       Date:  2011-01       Impact factor: 6.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.